Month: January 2023

Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indicationsWALTHAM, Mass., Jan. 04,...

Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV

Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant

REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming...

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...

Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with Hypoparathyroidism

-   The Expanded Access Program (EAP) allows physicians to request access to TransCon PTH, the company’s investigational parathyroid hormone replacement...

error: Content is protected !!